Oligopeptide Combi-Therapy of (resistant) steroidal cancers
Proprietary decapeptide drugs developed for tumor therapy of steroidal cancers (breast/mamma, ovarial, endometrial, prostate) and malignant melanoma. Mono-therapy or combi-therapy with current drugs possible due to huge synergism. Resensitization of tamoxifen resistant tumors and therapy of triple-negative breast cancer.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
